Długosz J W, Andrzejewska A, Nowak K, Wróblewski E, Dabrowski A
Department of Gastroenterology and Internal Medicine, Medical University of Białystok, Poland.
Rocz Akad Med Bialymst. 2005;50:230-6.
To assess effects of NF-kappaB activation inhibitor (pyrrolidine dithiocarbamate--PDTC) alone or with endothelins (ET-1, ET-2, ET-3) in early course of cerulein-induced acute pancreatitis (AP) in rats.
After 4 h of AP in Wistar rats, treated with PDTC 10 or 40 mg/kg or with PDTC 10 mg/kg and ET-1, ET-2 or ET-3, 0.5 or 1.0 nmol/kg twice i.p. in 1 h interval, free active trypsin (FAT), total potential trypsin (TPT) and lipase in 12000 x g supernatants of pancreatic homogenates, plasma alpha-amylase and histological changes were assayed. %FAT/TPT was an index of trypsinogen activation.
%FAT/TPT significantly increased to 12.42 +/- 2.14%, lipase to 5.51 +/- 0.84 U/mg protein and alpha-amylase to 28.5 +/- 5.61 U/mL in AP vs 1.96 +/- 0.31%, 1.29 +/- 0.11 U/mg and 5.80 +/- 1.38 U/ml in healthy control. Higher dose PDTC attenuated trypsinogen activation to 3.01 +/- 0.53% and alpha-amylase to 15.3 +/- 1.38. PDTC and ET-1 attenuated %FAT/TPT to 2.55 +/- 0.18% with lower and 2.34 +/- 0.44% with higher dose. ET-3 was less effective than ET-1: 6.76 +/- 0.46% with lower dose. Lower doses of ET-1 and ET-2 with PDTC, diminished lipase activity to 2.60 +/- 0.36 and 2.94 +/- 0.33.
Cumulative attenuation of trypsinogen activation after lower dose of PDTC and ET-1 approximated the effect of higher dose of PDTC. Additional effect of ET-3 was weaker than ET-1, and ET-2 was ineffective in this respect. The combination of this NF-kappaB activation inhibitor and ET-1 could be beneficial in early course of edematous AP by attenuating of trypsinogen activation. However, it should be treated with caution because of some unfavorable effects on histological scores of pancreatic injury.
评估核因子-κB(NF-κB)激活抑制剂(吡咯烷二硫代氨基甲酸盐--PDTC)单独使用或与内皮素(ET-1、ET-2、ET-3)联合使用对大鼠蛙皮素诱导的急性胰腺炎(AP)早期病程的影响。
Wistar大鼠发生急性胰腺炎4小时后,分别用10或40mg/kg的PDTC或10mg/kg的PDTC与0.5或1.0nmol/kg的ET-1、ET-2或ET-3腹腔注射治疗,间隔1小时注射两次。检测胰腺匀浆12000×g上清液中的游离活性胰蛋白酶(FAT)、总潜在胰蛋白酶(TPT)和脂肪酶、血浆α-淀粉酶以及组织学变化。FAT/TPT百分比是胰蛋白酶原激活的指标。
与健康对照组相比,急性胰腺炎组FAT/TPT百分比显著升高至12.42±2.14%,脂肪酶升高至5.51±0.84U/mg蛋白,α-淀粉酶升高至28.5±5.61U/mL,而健康对照组分别为1.96±0.31%、1.29±0.11U/mg和5.80±1.38U/mL。高剂量PDTC将胰蛋白酶原激活减弱至3.01±0.53%,α-淀粉酶减弱至15.3±1.38。PDTC与ET-1联合使用,低剂量时FAT/TPT百分比减弱至2.55±0.18%,高剂量时减弱至2.34±0.44%。ET-3的效果不如ET-1:低剂量时为6.76±0.46%。低剂量的ET-1和ET-2与PDTC联合使用,脂肪酶活性减弱至2.60±0.36和2.94±0.33。
低剂量PDTC和ET-1联合使用后对胰蛋白酶原激活的累积减弱作用接近高剂量PDTC的效果。ET-3的额外作用比ET-1弱,ET-2在这方面无效。这种NF-κB激活抑制剂与ET-1联合使用可能通过减弱胰蛋白酶原激活对水肿性急性胰腺炎的早期病程有益。然而,由于对胰腺损伤组织学评分有一些不利影响,应谨慎使用。